Spirox

Spirox DSCR

The Debt Service Coverage Ratio (DSCR) of Spirox (3055.TW) as of Nov 14, 2026 is -11.31. In the previous year, Debt Service Coverage Ratio (DSCR) was -2.37 — a change of 376.53% (lower).

DSCR

-11.31

YoY

376.53%

Last updated:

Debt Service Coverage Ratio (DSCR) of Spirox is 2025 -11.31 . Debt Service Coverage Ratio (DSCR) of Spirox was 2024 -2.37 . It decreases by 376.53% lower compared to the previous year.

The Spirox DSCR history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

DSCR
Date
DSCR
Jan 1, 2018
-17.46 TWD
Jan 1, 2019
-0.80 TWD
Jan 1, 2020
-0.24 TWD
Jan 1, 2021
-0.10 TWD
Jan 1, 2022
0.53 TWD
Jan 1, 2023
0.33 TWD
Jan 1, 2024
-2.37 TWD
Jan 1, 2025
-11.31 TWD
The Spirox DSCR history
YEARDSCRYoY
-11.31+376.53%
-2.37-825.43%
0.33-38.67%
0.53-615.66%
-0.10-57.42%
-0.24-69.78%
-0.80-95.39%
-17.46-691.78%
2.95+1,099.81%
0.25-98.82%
20.81—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Spirox Stock analysis

What does Spirox do? The Spirox Corporation is a company that was founded in 2007 and is headquartered in Menlo Park, California. The company operates in the medical technology industry and specializes in the development of products for nasal breathing. The mission of Spirox is to help people who have difficulty breathing through their nose. The company has recognized that many people have difficulty breathing through their nose due to congestion or other issues. Breathing through the mouth, however, can lead to a range of health problems such as dry mouth, sleep apnea, and respiratory infections. Therefore, Spirox has set out to develop innovative solutions to facilitate nasal breathing. Spirox's products include both implantable and non-implantable solutions. The company has a small but effective product portfolio consisting of two products: the Latera Nasal Stent and the AeroForm Nasal Stent. The Latera Nasal Stent is used to permanently open the nasal passages and facilitate breathing. The placement of the stent is a minimally invasive procedure that is typically performed on an outpatient basis. The Latera Nasal Stent is inserted and secured in the nasal wings to allow for better airflow through the nostrils. The stent is made of polydioxanone (PDO), a biocompatible polymer fiber that is absorbed by the body. Spirox's second product, the AeroForm Nasal Stent, is a non-implantable nasal stent used for temporary relief of nasal breathing. The AeroForm is a soft stent made of a flexible polymer material. It is inserted into the nasal passages and forms a gentle expansion to facilitate nasal breathing. As a company, Spirox focuses on collaboration with specialists and clinics to ensure that their products have high success rates. The company has established a partnership with the American Academy of Otolaryngology - Head and Neck Surgery (AAO-HNS) to advance scientific research and development in the nasal breathing industry. Spirox is led by experienced executives from the medical technology industry. The CEO, Duke Rohlen, has over 20 years of experience in leading medical technology companies such as Inspire Medical Systems and CV Ingenuity. The board team also includes Elektra Papadopoulos as Chair of the Board, who has worked at Hologic and Boston Scientific, among others. Although Spirox is a relatively small company, it has already received several awards. In 2017, the company was awarded the Red Herring Top 100 North America Award, which recognizes companies that are leading in the innovation industry. Overall, Spirox is an emerging company in the medical technology industry that offers innovative solutions to facilitate nasal breathing. Through collaboration with doctors and clinics and a focus on scientific research, the company aims to improve the success and effectiveness of its products. Spirox is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Spirox stock

Debt Service Coverage Ratio (DSCR) of Spirox is -11.31 in 2025.

Debt Service Coverage Ratio (DSCR) of Spirox changed from -2.37 to -11.31, representing a 376.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Service Coverage Ratio (DSCR) Spirox since 2006 – with annual values, charts, and detailed analysis.

The DSCR measures a company's ability to service its debt obligations from operating income. A ratio above 1.0 indicates sufficient income to cover debt payments.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt Service Coverage Ratio (DSCR)'s Spirox with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Spirox

All Key Metrics — Spirox